Edwards Lifesciences Corp (EW), the multinational medical equipment company, has seen a significant wave of events influencing its stock value. The company's price target has been revised multiple times, most recently raised to $74 and then to $75 from $69. Despite this, it has also recorded underperformance when compared to competitors on some days. The firm sees substantial backing, with approximately 85% of its shares being owned by
institutional investors, demonstrating the confidence that larger, established firms have in EW. However, it notably faces a Class Action Lawsuit, triggering concerns among investors.
Q4 2024 Earnings are expected to be disclosed soon, with the market anticipating the outcomes.
Evidence of strong
Growth in TMTT Sales was highlighted in the Q3 earnings call. On a negative note, the firm's stock plummeted due to missed earnings expectations and weak guidance, causing substantial losses to investors. An acquisition deal was also announced, where BD is set to acquire Edwards Lifesciences' Critical Care Product Group for $4.2 billion. As a result, its existing shareholders witnessed significant fluctuation in the stock value, despite a generally promising three-year underlying earnings growth.
Edwards Lifesciences Corp EW News Analytics from Mon, 03 Jun 2024 07:00:00 GMT to Sat, 11 Jan 2025 15:39:21 GMT -
Rating -1
- Innovation 4
- Information 6
- Rumor -7
